Clinical and angiographic outcome after coronary arterial stenting with the carbostent
Clinical and angiographic outcome after coronary arterial stenting with the carbostent
复制标题
DOI：
10.1016/s0002-9149(99)00874-7
复制
发表时间：
2000-04-01
影响因子：
2.8
通讯作者：
Galli, S
中科院分区：
文献类型：
--
作者：
Antoniucci, D;Bartorelli, A;Galli, S
Carbostent 是一种新型球囊扩张不锈钢管状支架，具有创新的多细胞设计和独特的涡轮层碳涂层 (Carbofilm)。这项开放式非随机 2 中心研究评估了患有天然冠状动脉疾病的患者植入卡博腾后的近期和长期临床和血管造影结果。 Carbostent 被植入 112 名患有 132 个新发病变的患者体内。大多数患者（55%）有不稳定型心绞痛，38%的病变为B2-C型。平均病灶长度为12.5+/-7.0mm，29%的病灶长度>15mm，未发生支架展开失败以及急性或亚急性支架血栓形成，6个月无事件生存率为84+/-4%。一名右冠状动脉支架植入且在血管造影随访中未出现再狭窄的患者在 6 个月后因非目标血管突然闭合而发生致命性梗塞而死亡。院内发生非Q波心肌梗死1例，11例再次靶病灶血运重建（靶病灶血运重建率10%）。 108 名患者 (96%)（127 个病灶）获得了 6 个月的血管造影随访。血管造影再狭窄率为11%。损失指数为0.29+/-0.28。这项研究的结果表明，Carbostent 对于预防这些相对高危患者的支架内血栓形成和再狭窄具有潜在益处。一项更大规模的试验正在计划中以证实这些有希望的结果。 (C)2000，Excerpta Medica, Inc.
The Carbostent is a new balloon-expandable, stainless steel, tubular stent with innovative multicellular design and unique turbostratic carbon coating (Carbofilm). This open nonrandomized 2-center study assesses the immediate and long-term clinical and angiographic outcomes after Carbostent implantation in patients with native coronary artery disease. The Carbostent was implanted in 112 patients with 132 de novo lesions. Most patients (55%) had unstable angina, and 38% of lesions were type B2-C. The mean lesion length was 12.5 +/- 7.0 mm, and 29% of lesions were >15 mm in length, No stent deployment failure occurred, as well as acute or subacute stent thrombosis, The 6-month event-free survival was 84 +/- 4%. One patient with a stented right coronary artery and no restenosis at the angiographic follow-up died after 6 months of fatal infarction due to abrupt closure of a nontarget vessel. In-hospital non-Q-wave myocardial infarction occurred in 1 patient, and 11 patients had repeat target lesion revascularization (target lesion revascularization rate 10%). The 6-month angiographic follow-up was obtained in 108 patients (96%) (127 lesions). Angiographic restenosis rate was 11%. The loss index was 0.29 +/- 0.28. The results of this study indicate a potential benefit of Carbostent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. A larger trial is being planned to confirm these promising results. (C)2000 by Excerpta Medica, Inc.